...
首页> 外文期刊>International Journal of Applied and Basic Medical Research >In Vivo Effects of nonselective, partially selective, and selective non steroidal anti-inflammatory drugs on lipid peroxidation and antioxidant enzymes in patients with rheumatoid arthritis: A clinical study
【24h】

In Vivo Effects of nonselective, partially selective, and selective non steroidal anti-inflammatory drugs on lipid peroxidation and antioxidant enzymes in patients with rheumatoid arthritis: A clinical study

机译:在类风湿关节炎患者脂质过氧化和抗氧化酶的非选择性,部分选择性和选择性非甾体抗炎药的体内效应:临床研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The relationship between oxidative stress, decreased antioxidant status, and rheumatoid arthritis (RA) has been widely investigated. To date, few clinical studies have assessed the role of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) in the modulation of oxidative stress in patients with RA. Aim: The aim of this study was to compare the effects of nonselective, partially selective, and selective cyclooxygenase (COX) inhibitors on markers of oxidative stress in patients with RA. Materials and Methods: Thirty RA patients were enrolled in this open label, prospective study for 12 weeks and randomly assigned to either group receiving diclofenac 100 mg, meloxicam 15 mg, or celecoxib 200 mg daily (n = 10 in each group). Patients were evaluated for superoxide dismutase (SOD) and serum malondialdehyde (MDA) as oxidative markers at the baseline and at the end of 12 weeks. Various parameters for efficacy were also assessed. Results: The baseline values of the SOD enzyme were significantly lower and MDA values were significantly elevated in patients randomized to the three treatment groups as compared to the control group (P 0.05). MDA level was significantly decreased in patients across all the treatment groups (P 0.05) after 12 weeks. There was an improvement in mean SOD enzyme levels at the end of 12 weeks; the difference for SOD was significant as compared to the baseline in the meloxicam group only (P 0.05) but not in diclofenac- and celecoxib-treated patients. Significant improvement was observed in all the treatment groups as regards patient assessment of pain visual analog scale, tender and swollen joint count, and patient global assessment. Conclusions: Diclofenac, meloxicam, and celecoxib carry antioxidant effects to a variable extent. NSAID possesses additional mechanism independent of COX inhibition which modulates oxidative stress.
机译:背景:氧化应激,降低抗氧化状态和类风湿性关节炎(RA)之间的关系已被广泛研究。迄今为止,很少有临床研究评估了常规的非甾体抗炎药(NSAID)在RA患者氧化胁迫调节中的作用。目的:本研究的目的是比较非选择性,部分选择性和选择性环氧化酶(COX)抑制剂对RA患者氧化胁迫标志物的影响。材料和方法:患者在该开放标签中注册,前瞻性研究12周,随机分配给接受双氯芬酸100mg,美洛昔康15mg或Celecoxib每日200mg(每组n = 10)。在基线和12周结束时评估患者的超氧化物歧化酶(SOD)和血清丙醛(MDA)作为氧化标志物。还评估了各种疗效参数。结果:与对照组相比,SOD酶的基线值显着降低,MDA值在三种治疗组随机患者中显着升高(P <0.05)。在12周后,所有治疗组的患者MDA水平显着降低(P <0.05)。 12周末的平均SOD酶水平有所改善;与Meloxicam组中的基线相比,SOD的差异很大(P <0.05),但不含双氯芬酸和塞克昔布治疗的患者。关于患者对疼痛视觉模拟规模,柔软和肿胀的关节计数以及患者全球评估的患者评估,在所有治疗组中观察到显着改善。结论:双氯芬酸,美洛昔康,塞克昔康携带抗氧化作用对可变程度。 NSAID具有独立于COX抑制的额外机制,其调节氧化应激。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号